source
- Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStarGilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.BioSpace · 18d ago↗ source
- STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sectorA new Treasury Department proposal would restrict U.S. investments in Chinese biotechs, but still allows licensing deals.STAT · 18d ago↗ source
- FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concernsAfter cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aa…